dihydroorotate dehydrogenase inhibitor

in Ph. I for RR-lymphoma

from opt. of literature molecule

Mol. Cancer Ther., Oct. 20, 2020

Agios Pharmaceuticals, Cambridge, MA

Structure of AG-636

AG-636 (Agios Pharmaceuticals dihydroorotate dehydrogenase (DHODH) inhibitor clinical candidate)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: